U.S. Markets closed

BioLineRx Ltd. (BLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7907+0.0208 (+2.70%)
At close: 04:00PM EDT
0.8300 +0.04 (+4.97%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7699
Bid0.7810 x 800
Ask0.8300 x 800
Day's Range0.7700 - 0.7999
52 Week Range0.5500 - 1.9800
Avg. Volume275,175
Market Cap49.656M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-1.7850
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
  • Insider Monkey

    BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript

    BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 Financial Results Conference Call. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications BioLineRx. Please go ahead. John Lacey: Thank […]

  • Zacks Small Cap Research

    BLRX: Confidence in a Strong Launch

    By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F . A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November

  • PR Newswire

    BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its audited 2022 annual financial results for the year ended December 31, 2022, and provided recent corporate and portfolio updates.